CERTIFICATE OF MAILING

1fw

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop <u>Disclosure</u> Commissioner for Patents, P.O. Box 1450,Alexandria, VA 22313-1450, on:

Date: 6/8/06

y: Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:)

Christian Birkner, et al.) EXAMINER: N/A

International Serial No.: 10/573,215) Art Unit: N/A

INTERNATIONAL FILING DATE: DECEMBER 1, 2004) Confirmation No. N/A

FOR: IMPROVED METHOD FOR BISULFITE) Attorney Docket: 22307-US

TREATMENT

INFORMATION DISCLOSURE STATEMENT

Mail Stop <u>Disclosure</u>. Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination

of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: 6/9

Rhea C. Nersesian Reg. No. 55,488

Correspondence Address: Roche Molecular Systems, Inc 1145 Atlantic Avenue Alameda, CA 94501 Tele: (510) 814-2800

Fax: (510) 814-2973

U.S. Department of Commerce Patent and Trademark Office Serial No. 10/573,215 Atty. Docket No. 22307-US ENFORMATION CITED BY APPLICANT Applicants: Birkner, et al. (Use several sheets if necessary) , JUN 1 2 2006 Group: Unassigned Filing Date: 01 December 2004 (International Filing Date) **U.S. PATENT DOCUMENTS** DOCUMENT ISSUE DATE NAME **SUBCLASS FILING DATE** * EXAMINER **CLASS** IF APPROPRIATE **INITIAL** NUMBER 91 10/25/85 4,683,202 07/28/87 Mullis, et al. 435 2 91 08/23/89 5,130,238 07/14/92 Malek, et al. 435 3 08/11/92 435 12/11/89 5,137,806 LeMaistre, et al 6 4 435 5,210,015 05/11/93 Gelfand, et al 6 08/06/90 5 5,234,809 08/10/93 Boom, et al 435 91 07/01/91 6 5,487,972 01/30/96 Gelfand, et al 435 6 01/05/93 7 5,552,277 09/03/96 Nelson, et al 435 6 07/19/94 8 435 91.2 02/17/95 5,595,890 01/21/97 Newton, et al 9 5,639,611 06/17/97 Wallace, et al 435 11/09/94 6 10 Herman, et al 01/03/96 5,786,146 07/28/98 435 6 11 5,804,375 09/08/98 Gelfand, et al 435 6 04/25/95 12 6,174,670 B1 01/16/01 Wittwer, et al 435 06/04/97 6 13 6,331,393 B1 12/18/01 Laird, et al 435 05/14/99 6 FOREIGN PATENT DOCUMENTS **DOCUMENT NUMBER PUBLICATION** COUNTRY TRANSLATION **CLASS SUBCLASS** DATE PCT/EP2004/013627 03/02/05 PCT Search Report DE 10050942 A1 15 4/18/02 DE DE 374 442 A1 02/02/89 16 DE 17 0 200 362 B1 12/10/86 EP 0 201 184 A2 12/17/86 EP 18 0 389 063 A2 19 09/26/90 EP 0 439 182 A2 07/31/91 EP 03/03/04 1 394 172 A1 EP 21 1 443 052 A1 22 08/04/04 EP WO 90/01069 02/08/90 PCT WO 90/06045 06/14/90 **PCT**

Attorney Docket: 22307-US Serial No. 10/573,215 International Filing Date: December 1, 2004 Page 2 of 3

	25	WO 92/02638	02/20/92	PCT					
	26	WO 96/41811	12/27/96	PCT					
	27	WO 99/16781	04/08/99	PCT		-	 		
	28	WO 99/40098	08/12/99	PCT			 		
	29	WO 00/32762	06/08/00	PCT	-				
	30	WO 00/37291	06/29/00	PCT		<u> </u>	_		
	31	WO 01/37291 A1	05/25/01	PCT					
	32	WO 01/98528 A2	12/27/01	PCT	· · · · · ·				
	33	WO 02/31186 A2	04/18/02	PCT				<u> </u>	
	34	WO 2005/054502 A1	06/16/05	PCT				 - -	
		princh - 1-interactor (10) - 1, miles p open r verse e vagen p				- A-TERIGI			
	1	OTHER ART (Incl						_	
	35	Abramson, R., et al., 1993, "Nucleic acid amplification technologies", Current Opinion in Biotechnology, 4:41-47							
	36	Alderton, R., et al., 1992, "M	lagnetic Bead Pur	rification of M13 DN	A Seguenc	ing Template	s". Analut	ical	
		Biochemistry, 201 :166-169					· ,		
	37	Ausubel F., et al., 2001, "Current Protocols In Molecular Biology", John Wiley & Sons, Inc., Supplement 55-							
		56:1-10		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	y C = = :::,	0 - F F		
	38								
	39	Barany, F., 1991, "Genetic disease detection and DNA amplification using cloned thermostable ligase", <i>Proc. Natl. Acad. Sci. USA</i> , 88 :189-193							
	40								
	41								
	42								
	43		 		positive c	lisplay of 5-m	ethylcyto	sine	
		Frommer, M., 1992, "A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands", <i>Proc. Natl. Acad. Sci. USA</i> , 89: 1827-1831							
	44	· · · · · · · · · · · · · · · · · · ·						431436	
	45	Grigg, G., 1996, "Sequencing 5-methylcytosine residues by the bisulphate method", The Journal of Seq.&Mapping 6:189-198							
	46	Grunau, C., et al., 2001, "Bisulfite genomic sequencing: systematic investigation of critical experimental parameters", <i>Nucleic Acids Research</i> , 29 (13e65):1-7							
	47	Guatelli, J., et al., 1990, "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", Proc. Natl. Acad. Sci. USA, 87:1874-1878							
	48	Jakobi R., et al., 1988, "Filter	-Supported Prepa	aration of λ Phage D	NA", Ana	lytical Biochen	istry, 175	:196-201	
	49	Komlyama, M., et al., 1994, "Catalysis of Diethylenetriamine for Bisulfite-Induced Deamination of Cytosine in Oligodeoxyribonucleotides", <i>Tetrahedron Letters</i> , 35 (<u>44</u>):8185-8188							

Attorney Docket: 22307-US Serial No. 10/573,215 International Filing Date: December 1, 2004 Page 3 of 3

	50	Kwoh, D., et al., 1989, "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format", <i>Proc. Natl. Acad. Sci. USA</i> , 86:1173-1177				
51 52 53		Marko, M., et al., 1982, "A Procedure for the Large-Scale Isolation of Highly Purified Plasmid DNA Using Alkaline Extraction and Binding to Glass Powder", <i>Analytical Biochemistry</i> , 121 :382-387				
		Morrow, C., et al., 1989, "Structure of Human Genomic Gluthathione S-transferase-A gene", Gene, 75:3-11				
		Oakeley, E., 1999, "DNA methylation analysis: a review of current methodologies", <i>Pharmacology & Therapeutics</i> , 84: 389-400				
	54	Olek, A., et al., 1996, "A modified and improved method for bisulphate based cytosine methylation analysis", <i>Nucleic Acids Research</i> , 24 (<u>24</u>):5064-5066				
	55	Paulin, R., et al., 1998, "Urea improves efficiency of bisulphate-mediated sequencing of 5'-methylcytosine in genomic DNA", <i>Nucleic Acids Research</i> , 26 (<u>21</u>):5009-5010				
	56	Raizis, A., et al., 1995, "A Bisulfite method of 5-Methylcytosine Mapping That Minimizes Template Degradation", Analytical Biochemistry, 226:161-166				
	57	Vogelstein, B., et al., 1978, "Preparative and analytical purification of DNA from agarose", <i>Proc. Natl. Acad. Sci. USA</i> , 76(2) :615-619				
	58	Warnecke, P., et al., 2002, "Identification and resolution of artifacts in bisulfite sequencing", <i>Methods</i> , 27 :101-107				
	59	Whelen, A., et al., 1996, "The Role of Nucleic Acid Amplification and Detection in the Clinical Microbiology Laboratory", Annu. Rev. Microbid, 50:349-379				
	60	Wu, D., et al., 1989, "The Ligation Amplification Reaction (LAR) - Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation				
EXAMINER6		DATE CONSIDERED				

conformance and not considered. Include copy of this form with next communication to applicant.